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Background-—The treatment of mycotic abdominal aortic aneurysm requires surgery and antimicrobial therapy. Since prosthetic
reconstructions carry a considerable risk of reinfection, biological grafts are noteworthy alternatives. The current study evaluated
the durability, infection resistance, and midterm outcome of biological grafts in treatment of mycotic abdominal aortic aneurysm.
Methods and Results-—All patients treated with biological graft in 6 countries between 2006 and 2016 were included. Primary
outcome measures were 30- and 90-day survival, treatment-related mortality, and reinfection rate. Secondary outcome measures
were overall mortality and graft patency. Fifty-six patients (46 males) with median age of 69 years (range 35–85) were included.
Sixteen patients were immunocompromised (29%), 24 (43%) had concomitant infection, and 12 (21%) presented with rupture.
Bacterial culture was isolated from 43 (77%). In-situ aortic reconstruction was performed using autologous femoral veins in 30
patients (54%), xenopericardial tube-grafts in 12 (21%), cryopreserved arterial/venous allografts in 9 (16%), and fresh arterial
allografts in 5 (9%) patients. During a median follow-up of 26 months (range 3 weeks–172 months) there were no reinfections and
only 3 patients (5%) required assistance with graft patency. Thirty-day survival was 95% (n=53) and 90-day survival was 91%
(n=51). Treatment-related mortality was 9% (n=5). Kaplan–Meier estimation of survival at 1 year was 83% (95% conﬁdence interval,
73%–94%) and at 5 years was 71% (52%–89%).
Conclusions-—Mycotic abdominal aortic aneurysm repair with biological grafts is a durable option for patients ﬁt for surgery
presenting an excellent infection resistance and good overall survival. ( J Am Heart Assoc. 2018;7:e008104. DOI: 10.1161/
JAHA.117.008104.)
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M ycotic aortic aneurysms (MAA)—the term ﬁrstdescribed as a septic embolic complication of endo-
carditis—is currently being used for any aneurysm secondary
to aortic infection.1 MAAs are a rare, but life-threatening
entity with rapid clinical course and devastating outcomes
without surgical intervention.2 Even with adequate treatment,
mortality remains as high as 18% to 43%.3–7
Bacterial infection inoculates the arterial wall through a
damaged intimal layer, resulting in destroyed media or
occluded vasa vasorum with secondary arterial wall ischemia.
The weakened wall loses its elasticity and is predisposed to
aneurysm formation.8 Rapid aneurysmal growth induces pain
and infection, which may promptly evolve to sepsis. Patients
are often immunosuppressed and/or have concomitant
infections; therefore, early diagnosis, adequate antimicrobial
therapy, and surgery are crucial for favorable outcomes.3,9,10
The feasibility of in-situ prosthetic grafting or endovascular
aortic repair (EVAR) of mycotic abdominal aortic aneurysms
(MAAA) has been acknowledged by previous studies.10–15
Minimally invasive EVAR provides a favorable early survival
rate at 3 months, but the risk of reinfection and associated
late mortality remains a problem.10–13 Because of poor
outcomes in graft patency, aortic stump blow-out and
numerous reinfections, extra-anatomical bypass has been
abandoned as a treatment of choice in many centers.16 In-situ
prosthetic alignment is the preferred alternative to EVAR, yet
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a substantial rate of mortality persists because of infectious
complications.10,11,15
Earlier studies have shown biological vascular grafts to be
more resistant to microbial infection than synthetic
analogues.17,18 Autologous femoral veins, allografts, and
recently added self-made xenopericardial tubes are the most
frequently used biological materials in aorto-iliac position.
They have been applied successfully as a reconstruction
material in case of aortic graft infection; however, their
performance in treatment of MAAA lacks evidence.19–23
The purpose of this study was to ascertain the experience
using biological grafts in the treatment of MAAA by assessing
reinfection rate, graft-related complications, and treatment-
related and midterm survival.
Methods
Because of regulations for the protection of privacy, the data,
analytic methods, and study material will not be automatically
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. However, data
could be made available within limits of legal regulations of
patient data access upon reasonable request to the corre-
sponding author.
All consecutive patients treated for MAAA with abdominal
aorto-iliac in-situ reconstruction with biological material in
collaborating centers from January 2006 to December 2016
were included (Table 1). Patient data were collected from
vascular registries and hospital records by investigators.
Identical data collection sheets were ﬁlled out in collaborating
centers from 6 countries and eligibility was revised in Helsinki
University Hospital. Two patients included were treated earlier
than 2006, since data on MAAA patients were available from
earlier years in 2 centers. Patients who had mycotic
aneurysms, but were primarily operated on with EVAR as a
bridging method or with prosthetic graft, were excluded.
Diagnosis of mycotic aortic aneurysm was deﬁned by the
presence of 2 or more of the following criteria: clinical
presentation (pain, fever, and sepsis), laboratory parameters
(elevated leukocyte count and C-reactive protein, positive
cultures from blood or aortic tissue), and radiologic ﬁndings
on computed tomography or magnetic resonance imaging
(saccular/multilobular aneurysm, periaortic soft tissue mass,
or gas). The diagnosis was conﬁrmed with intraoperative
infectious ﬁndings of MAAA. Reinfection was deﬁned as graft
infection, aorto-enteric ﬁstula, or recurrent MAA.
Type of biological graft used was decided by the collab-
orating center based on availability, previous experience, and
patient’s clinical condition. In Helsinki, Aarhus, and Sweden,
autologous femoral veins are the preferred reconstruction
material in case of vascular infection; in Bern and Nancy, self-
made pericardial tubes are used or cryopreserved arterial
allografts if available. Siena prefers fresh arterial allografts
and therefore availability is the main limiting factor for
biological reconstruction. Autologous femoral veins were
harvested simultaneously with aortic exposure by a second
team. The valves were resected and veins were used as
straight tubes or sewn together into pantaloon conﬁguration
with nonabsorbable polypropylene running suture. Upper
anastomosis was reinforced with patients’ fascia lata.20
Preparation of the pericardial tube graft was performed by
tailoring a large bovine pericardial patch according to the
desired size for aortic reconstruction. Then it was sewn to
construct a tube using a polypropylene 4–0 suture.23
Cryopreserved arterial allografts were commercial, thawed
and handled as instructed by the providing cryobank. Fresh
arterial allografts were rinsed in antibiotic solution for a
minimum of 15 minutes after harvesting and were implanted
immediately.
The collected data included demographic parameters (sex,
age, smoking), comorbidities (hypertension, diabetes mellitus,
ischemic heart disease, cerebrovascular disease, chronic
obstructive pulmonary disease, renal insufﬁciency and dialysis
treatment, steroid treatment or immunosuppressive condi-
tion), clinical signs (abdominal/back pain, fever, additional
infection, sepsis), laboratory results (C-reactive protein, white
blood cell count, blood culture, tissue culture from operating
ﬁeld), radiological ﬁndings (aneurysm location, saccular/
multilobular aneurysm, periaortic soft tissue mass or gas,
aneurysm size and location, rupture), and whether 18F-
ﬂuorodeoxyglucose positron emission tomography /computed
tomography were performed to conﬁrm the diagnosis. Oper-
ative data included type of aortic reconstruction and
Clinical Perspective
What Is New?
• High rate of reinfection and subsequent mortality are linked
to prosthetic treatment of mycotic abdominal aortic
aneurysms, but durability of biological reconstruction
material in primary aortic infections lacks evidence.
• Current study on largest cohort of patients treated with
open repair and biological grafts shows no reinfections,
good graft patency, and acceptable mortality.
What Are the Clinical Implications?
• Because of low postoperative mortality and good long-term
graft durability, patients ﬁt for open surgery should be
considered for in-line reconstruction with biological
material.
• Surgical treatment with biological material spares patients
from lifelong antimicrobial therapy and related complications.
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concomitant procedures, used graft material, renal protection
if needed in case of suprarenal cross-clamping, operation time,
blood loss, and clamping time. Postoperative data included
length of intensive care unit and hospital stay, postoperative
complications, follow-up time, graft-related complications and
interventions, major amputations, 30-day, treatment-related,
and late mortality and cause of death. Data on antibiotics used
were collected from the pre- and postoperative period; also the
length of antibiotic treatment, from diagnosis to operation and
postoperatively, was recorded.
Statistical analysis was performed using SPSS 22 software
(IBM Corp, Armonk, NY). Continuous variables are expressed
as median (range). All statistical tests were 2-tailed, and a
P<0.05 was considered signiﬁcant. Univariable analysis was
performed to analyze associated risk factors for mortality at
30 days, and treatment-related and overall mortality were
determined using Fisher exact test and binary logistic
regression. The following variables were tested: sex, age,
smoking, hypertension, diabetes mellitus, ischemic heart
disease, cerebrovascular disease, chronic obstructive pul-
monary disease, renal insufﬁciency and dialysis treatment,
steroid treatment or immunosuppressive condition, concomi-
tant infection, C-reactive protein at the time of diagnosis and
operation, aneurysm rupture, operation time, blood loss,
suprarenal clamping requiring renal protection, clamping time,
additional vascular reconstruction to aortic reconstruction,
other concomitant procedure, Salmonella versus non-Sal-
monella infection, and positive versus negative culture.
The multivariable Cox regression analysis for overall
survival was performed using variables with P<0.2 in the
univariable analysis. The survival analysis was performed
according to the Kaplan–Meier method.
The study had clinical approval. Because of the retrospec-
tive nature of the research, permission from the ethical
committee was not required.
Results
During the studyperiod, 22 432abdominal aortic aneurysmswere
treated in collaborating centers, of which 187 (0.8%) wereMAAAs.
Eighty of 187patientswere treatedwith EVAR (43%), 51 (27%)with
open prosthetic repair, and 56 (30%) with biological material.
Sweden was the only participating country where the preferred
treatment for MAAA is prosthetic grafting or EVAR (n=111/120,
93%). In other collaborating centers, biological reconstruction is
ﬁrst line of treatment and prosthetic reconstruction was used only
in case of patients in poor condition, misdiagnosis, emergency,
lack of biological material, or as a bridging method. Only patients
operated on with biological material as a primary treatment
method were included in the study.
There were 46 (82%) men and 10 (18%) women with a
median age of 69 years (range 35–85). Fifteen (27%) patients
presented with sepsis at arrival to the center with vascular
surgery service and 3 (5%) were septic at the time of
operation. Patient characteristics, clinical presentation, and
operative details are listed in Table 2.
Blood and/or tissue culture were positive in 43 (77%) cases,
10 (18%) were positive for Salmonella spp. and 33 (59%) for non-
Salmonella infection. Identiﬁed microorganisms are listed in
Table 3. Antimicrobial therapy was assigned based on the
susceptibility of the isolated strains. Duration was designated
individually based on isolated strains, concurrent infections,
clinical severity of the infection, and postoperative course of
events. Median time of antibiotic therapy preoperatively was
1 week (ranging from a few hours to 13 weeks), and postop-
eratively 8.5 weeks (range 1–35). At the end of follow-up, in 3
cases the full duration of antimicrobial therapy remained
unknown because of short follow-up time. Lifelong therapy was
not necessary in any case.
Postoperative complications necessitating reoperation
occurred in 16 (29%) of the patients, but none of them were
Table 1. Patients Treated for AAA and MAAA in the Collaborating Centers and Registries
Center
Operated
AAA/MAAA
Reconstruction Material for MAAA
EVAR
Prosthetic
Graft
Autologous
FV
Bovine
Pericard
Cryopreserved Arterial/
Venous Allografts
Fresh
Allografts
Finland Helsinki University Hospital 1093/21 4 2 13  0/2 
Denmark Aarhus University Hospital 1236/10  2 8   
Italy Siena University Hospital 643/9 2 2    5
France Nancy University Hospital 2100/7 2 1  2 2/0
Switzerland* Bern University Hospital 2230/20 2 3  10 5/0 
Sweden† Register data, incl. 28 hospitals 15 130/120 70 41 9   
Total 22 432/187 80 51 30 12 7/2 5
AAA indicates abdominal aortic aneurysm; EVAR, endovascular aortic repair; FV, femoral vein; MAAA, mycotic abdominal aortic aneurysm.
*Data-collection period January 2002 to December 2016, includes patient treated with biological graft before 2006.
†Data collection period January 2001 to December 2014, includes 1 patient treated with biological graft before 2006.
DOI: 10.1161/JAHA.117.008104 Journal of the American Heart Association 3
Biological Repair of Mycotic Aortic Aneurysms Heinola et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 9, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
graft related. Medical complications occurred in 14 (25%), of
which severe renal dysfunction was most prevalent. Recorded
postoperative complications are listed in Table 4.
Median stay in the intensive care unit was 1 day (range 0–
30) and in the vascular surgery department was 18 days
(range 7–60). The vast majority of the patients were
transferred to other medical facilities to continue intravenous
antimicrobial therapy or rehabilitation, but detailed informa-
tion on this is lacking.
Table 2. Preoperative Characteristics and Operative Details
Total Amount of Patients, n (%) 56 (100)
Male, n (%) 46 (82)
Age (y), median (range) 69 (35–85)
Preoperative conditions, n (%)
Hypertension 44 (79)
Coronary heart disease 17 (30)
COPD 12 (21)
Renal insufficiency/dialysis 9 (16)
Diabetes mellitus 16 (29)
Cerebrovascular disease 5 (9)
Smoking 31 (60)
Immunocompromising condition 16 (29)
Alcohol abuse 8 (14)
Steroid treatment 3 (5)
Renal failure 3 (5)
HIV 1 (2)
Other 3 (5)
Clinical presentation, n (%)
Fever 42 (75)
Abdominal/back pain 50 (89)
Concomitant infection 24 (43)
Gastroenteritis 7 (13)
Spondylodiscitis 4 (7)
Pneumonia 4 (7)
UTI 3 (5)
Cellulitis 2 (4)
Cholecystitis 2 (4)
Septic arthritis 1 (2)
Infected Charcot foot 1 (2)
Parodontitis 1 (2)
Endocarditis 1 (2)
Herpes Zoster 1 (2)
Median WBC count at the
time of diagnosis, 9109/L (range)
14 (3.6–31)
Median WBC count at the
time of operation, 9109/L (range)
8.8 (3.7–27.7)
Median CRP level at the
time of diagnosis, mg/L (range)
132 (6–407)
Median CRP level at the
time of operation, mg/L (range)
41 (3–407)
Aneurysm characteristics, n (%)
Aneurysm location
Suprarenal/visceral 6 (11)
Para-/juxtarenal 6 (11)
Continued
Table 2. Continued
Total Amount of Patients, n (%) 56 (100)
Infrarenal 41 (72)
Iliac 2 (4)
Multiple 1 (2)
Periaortic soft tissue edema 45 (80)
Periaortic/intravascular gas 7 (13)
Saccular, multilocular aneurysm 42 (75)
Rupture 12 (21)
Median aortic aneurysm size, mm (range) 46 (30–80)
Perioperative details, n (%)
Aortic reconstruction
In-situ aorto-aortic/aorto-iliac reconstruction 55 (98)
Aortic patch-plasty with venous
visceral reconstruction
1 (2)
Aortic reconstruction material
Autologous femoral veins 30 (54)
Bovine pericardial self-made tube 12 (21)
Fresh arterial allografts 5 (9)
Cryopreserved arterial allografts 7 (12)
Cryopreserved venous allografts 2 (4)
Adjunctive procedure 16 (29)
Visceral vascular reconstruction 13 (23)
Gastrointestinal procedure 3 (5)
Renal protection used 15 (27)
Cold fluid infusion 9 (16)
Temporary shunts 3 (5)
Extracorporeal perfusion 1 (2)
N/A 2 (4)
Omental coverage of aortic reconstruction 23 (41)
Open abdomen treatment postoperatively 17 (30)
Median operation time, min (range) 270 (150–590)
Median aortic clamping time, min (range) 92 (25–257)
Median blood loss, mL (range) 1700 (200–17 000)
COPD indicates chronic obstructive pulmonary disease; CRP, C-reactive protein; HIV,
human immunodeﬁciency virus; N/A, not available; UTI, urinary tract infection; WBC,
white blood cell count.
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Outcomes
The median follow-up time was 26 months (range 3 weeks–
172 months). The Kaplan–Meier survival estimates at 30 days
was 95% (95% conﬁdence interval [CI], 89%–100%), 91% at 90
days (CI, 82–99%), 83% at 1 year (CI, 73%–94%), and 71% at 5
years (CI, 52%–89%). For details see Figure. Overall treatment-
related mortality was 9% (n=5) (Table 5).
In the univariable analysis, none of the variables was
signiﬁcantly associated with 30-day mortality. Need for renal
protection during suprarenal clamping (P=0.015), operation
time (P=0.046), and C-reactive protein level at the time of
diagnosis (P=0.049) were associated with treatment-related
mortality. Smoking was the only factor associated with higher
overall mortality (P=0.034) (Figure), while negative bacterial
culture was associated with lower mortality (P=0.026). In a Cox
regression model using variables with P<0.2, smoking (hazard
ratio 10.1; 95%CI, 1.09–92.96; P=0.042) and level of C-reactive
protein at the time of diagnosis (hazard ratio 1.0; 95% CI, 1.00–
1.01; P=0.013) were associated with all-cause mortality.
There were no reinfections diagnosed, and the overall
freedom from graft interventions was 95% (n=53). One patient
had graft limb thrombosis treated with thrombectomy, and 2
patients needed percutaneous transluminal angioplasty for
graft limb stenosis. No grafts were lost during the follow-up.
Discussion
This study is the result of an international collaboration
between 6 different countries and is to date the largest cohort
of patients treated with open repair and biological grafting for
the MAA with an abdominal location. The study demonstrates
a survival of 95% at 30 days and 71% at 5 years, which is
comparable to the treatment of elective degenerative abdom-
inal aortic aneurysm (30-day and 5-year survival for EVAR 98%
and 67%, for open repair 95% and 75%, respectively).19 During
the follow-up time, there were no reinfections and only 3
patients required interventions to maintain graft patency.
Despite the variety of biological grafts used, there were no
graft-related fatal complications.
The infection resistance and long-term outcome of biolog-
ical grafts in treatment of mycotic aneurysms has been
reported earlier in small case series or mixed with data on
aortic graft infection.20,22–24 Patients with aortic graft
Table 3. Isolated Microorganisms
Total Amount of Patients With Positive Culture, n (%) 43 (77)
Salmonella spp. 10 (18)
Non-Salmonella strains 33 (59)
Staphylococcus aureus/MRSA 15/3 (27/5)
Streptococcus spp. 7 (13)
Echerichia coli 5 (9)
Candida spp. 2 (4)
Campylobacterium spp. 2 (4)
Brevibacterium casei 1 (2)
Eikenella corrodens 1 (2)
Bacteroides fragilis 1 (2)
Fusiobacterium necrophorum 1 (2)
Yersinia enterocolitica 1 (2)
MRSA indicates methicillin-resistant Staphylococcus aureus.
Table 4. Postoperative Complications
Total Amount of Patients, n (%) 56 (100)
Surgical complications, n (%) 16 (29)
Reoperation because of bleeding 6 (11)
Leg hematoma 2 (4)
Diffuse abdominal bleeding 2 (4)
GI bleeding 2 (4)
Spleen 1 (2)
Reoperation because of ischemia 3 (5)
Lower limb ischemia/amputation 2/1 (4/2)
Renal ischemia 1 (2)
GI and urologic complications 5 (9)
Ileus 2 (4)
Duodenal lesion 1 (2)
Cholecystitis 1 (2)
Ureteral lesion 1 (2)
Other
Wound complications 3 (5)
Occlusion of av-fistula 1 (2)
Medical complications, n (%) 14 (25)
Severe renal dysfunction 9 (16)
New-onset dialysis, temporary/permanent 7/2 (13/4)
Cardiac complications 2 (4)
Respiratory complications 1 (2)
Acute stroke 1 (2)
Other
Delirium 4 (7)
Wound infection 2 (4)
Paraparesis 1 (2)
HIT 1 (2)
Hyperalgesia 1 (2)
av-ﬁstula indicates arteriovenous ﬁstula; GI, gastrointestinal; HIT, heparin-induced
thrombocytopenia.
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infection are challenging; in addition to highly prevalent
cardiovascular risk factors, operating in scar tissue compli-
cates the treatment even further. Concentrating exclusively
on treatment of MAAA makes the current cohort more
homogeneous and strengthens the study. Although consec-
utive patients were included, only 12 (21%) of them presented
with rupture and 6 (11%) of MAAAs encompassed suprarenal
aorta. Rupture and suprarenal aneurysm location are known
to be associated with increased risk of aneurysm-related
death.3,4,11,12 Suprarenal location in combination with sys-
temic inﬂammatory response system diminishes survival even
further. Patients presenting with systemic inﬂammatory
response system are also at higher risk for reinfection and
subsequent mortality; therefore, prosthetic reconstruction
should be used with caution in these patients.25
Cryopreservation has improved the permanence of allo-
grafts, but degeneration, possible aneurysmatic dilatation,
and subsequent rupture remain challenging.22,26–28 Also,
availability and costs limit more widespread use. Furthermore,
5 patients in the present study were treated with fresh
allografts, which are known to have even higher risk for
complications.26 Despite the lack of signs of degeneration in
the current cohort, we call for caution and suggest using
autologous femoral veins or cryopreserved allografts if
possible. Femoral veins as autologous material have shown
excellent performance related to long-term infectious compli-
cations, but time-consuming harvesting is a limitation in a
center unable to recruit a second team of surgeons.20,21 Graft
durability is acceptable, balloon angioplasty is occasionally
needed, and overall long-term patency is >90%.20,21 In the
current study, autologous femoral veins were used in 30
patients with primary patency of 90% and primary assisted/
secondary patency of 100%.
Xenopericardial tubes in the current material were self-
made from xenopericardial patch, but presently commercial
options are available as well. Made of bovine, porcine, or
equine pericardium, they are easy to handle, readily available,
and additionally are resistant to several endospores, microor-
ganisms, and viruses, because of glutaraldehyde solution.29
Earlier reports on self-made xenopericardial tubes have
been encouraging with no graft-related late mortality or
reinfections.23,24,30 The present study yielded correlating
results, but the considerably small number of patients in all of
them calls for further investigations.
EVAR have been enthusiastically adopted to treat MAAA.
Signiﬁcantly lower postoperative morbidity and mortality are
the beneﬁts of EVAR, allowing treatment of older and sicker
patients who would otherwise be given palliative treat-
ments.31 However, long-term survival seems inferior to open
treatment in case of degenerative aortic aneurysm repair, so
that conventional surgery may be advantageous to younger
populations in case of MAAA as well.32 In a nationwide study
by S€orelius et al, excellent early survival of 96% at 3 months
was presented after endovascular treatment of MAAA. Still, a
reinfection rate of 24%, strongly linked to late mortality,
indicates the hidden danger of prosthetic graft implantation
among infected tissue.11 Similar results were seen in an
international multicenter study with 3-month survival of 86%
BA
Figure. Kaplan–Meier curves demonstrating overall 5-year survival (A) and among smokers vs nonsmokers (B). *No data available
about smoking status in 3 patients.
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and reinfection rate of 27%.10 Biological grafts showed no
reinfections, nor graft-related fatal complications; 5-year
survival of 71% was superior to previous studies with
prosthetic grafts, but graft durability and overall superiority
need longer follow-up and further studies.10,11,15
Prosthetic in-situ reconstruction is a conventional alterna-
tive to biological grafts. Infected tissue can be debrided
and copious saline irrigation performed. Some centers
prefer rifampicin-soaked Dacron grafts, possibly providing
extra protection against gram-positive cocci.3,14,33,34
Omental-pedicle cover is as important as in biological
reconstructions.3,14,20–22,34 The postoperative mortality has
no advantage to biological grafts and reinfection rate ranges
12% to 18%.11,15 Hsu et al reported a reinfection rate and
total graft-related mortality of 5% during 2-year follow-up.35
However, the number of patients was small, the vast majority
had Salmonella infection, known as a predictive factor for
superior outcome, and numerous patients were in good
general condition receiving antimicrobial treatment preoper-
atively for 4 to 6 weeks.2,10,35
Antimicrobial therapy is a crucial part of complex treat-
ment of MAAA. It should be started intravenously as early as
possible with broad-spectrum antibiotics or based on sus-
ceptibility of the available strains. Articles published on
prosthetic reconstructions emphasize preoperative antimicro-
bial therapy at least 1 week for stable patients to eliminate
bacteremia and impregnate surrounding tissue with antibi-
otics, yet the evidence for less postoperative infectious
complications is lacking.7,12,35 The duration of antimicrobial
therapy remains unclear, depending on the surgical method
and postoperative course, varying from 6 weeks to life-
long.10–12,35,36 With close surveillance, antibiotics may be
Table 5. 30-Day and Treatment-Related Mortality
Age (y) Presentation
Immunosuppressive
Condition Rupture
Urgent
Operation
MAAA Location
and
Reconstruction Microbiology
Postoperative
Complications
Cause of
Death
Postoperative
Day of Death
67 Abdominal pain,
fever, enteritis
No No No Infrarenal,
in-situ
reconstruction
with FV
Salmonella Myocardial
infarction
Acute
myocardial
infarction
3
74 Abdominal pain No No No Juxtarenal,
in-situ with
cryopreserved
allograft
and renal
bypass
Staph.
aureus
Left limb
amputation
because of
gangrene,
stroke,
hyperalgesia
Acute stroke 5
73 Abdominal
pain, fever,
spondylodiscitis
No No Yes Juxtarenal,
in-situ
reconstruction
with bovine
pericard and
bilateral renal
artery
reimplantation
MRSA Bilateral renal
ischemia,
renal failure,
paraplegia,
sepsis
MODS 23
56 Abdominal pain,
septic, infected
gangrene
Alcohol abuse Yes Yes Suprarenal,
in-situ
reconstruction
with
bovine pericard
and renal
arteries
reimplantation
Staph.
aureus
GI bleeding,
myocardial
infarction,
ARDS
Acute
myocardial
infarction,
sepsis
88
54 Abdominal pain,
sepsis, septic
arthritis
No Yes Yes Visceral, aortic
patch plasty
and
renal artery
reconstruction
with FV
Staph.
aureus
Renal failure,
sepsis
MODS 120
ARDS indicates acute respiratory distress syndrome; FV, femoral vein; GI, gastrointestinal; MAAA, mycotic abdominal aortic aneurysm; MODS, multiorgan dysfunction syndrome; MRSA,
methicillin-resistant Staphylococcus aureus.
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discontinued in selected cases, provided there is no clinical,
hematological, or radiological prove of ongoing infection. In
the present study, the median time for antibiotic treatment
was 8 weeks postoperatively, and no in-hospital survivor
needed lifelong treatment.
Salmonella infections cause more rapid aneurysm growth
and rupture, strongly affecting the natural course of the
disease. Yet non-Salmonella infections are known to be
associated with higher aneurysm-related complications and
death after treatment.2,3,10,36 In the current study, none of
them was signiﬁcantly associated with death or reinfections.
However, negative culture was associated with overall survival,
suggesting the beneﬁt of the elimination of active bacteria
before surgery to produce a more favorable outcome.10,35
The main limitation of the study was lack of comparison
between in-situ reconstruction with biological grafts and other
treatment methods. However, the vast majority of patients
treated with EVAR (n=70/80) or open prosthetic reconstruc-
tion (n=41/51) were from the Swedish national registry
(Table 1), and patients treated from 2006 to 2014 were
included in the nationwide study published by S€orelius et al.11
Therefore, the results of S€orelius’ study and the current study
are being considered as somewhat comparable. None of the
centers that participated have reliable data on patients
treated with medical treatment only; therefore, the possibility
of case selections exist. However, since aneurysm-related
mortality is >60% with sole medical treatment in case of
mycotic aortic aneurysms, conservative treatment was
decided only in rare cases of palliative care or unﬁtness of
any intervention.15 MAAAs are extremely rare; therefore,
organizing a randomized controlled multicenter trial would be
particularly challenging with so few patients per institution.
The retrospective nature of the study causes a possibility of
selection bias, and makes it impossible to standardize follow-
up protocols in different centers and acquire missing data
from collaborators. The small number of patients sets
limitations for statistical analyses.
Conclusion
There is no consensus on surgical treatment of MAAA
because of the complexity of the disease and lack of obvious
superiority of any single treatment method. Open repair with
biological grafting for MAAAs demonstrated a midterm
survival that was higher compared with other methods, most
likely because of no reinfections. The surgical approach also
carries acceptable morbidity for patients who are ﬁt for open
surgery.
Disclosures
None.
References
1. Osler W. The gulstonian lectures, on malignant endocarditis. BMJ.
1885;1:467–470.
2. Hsu RB, Chang CI, Wu IH, Lin FY. Selective medical treatment of infected
aneurysms of the aorta in high risk patients. J Vasc Surg. 2009;49:66–70.
3. Oderich GS, Panneton JM, Bower TC, Cherry KJ Jr, Rowland CM, Noel AA, Hallett
JW Jr, Gloviczki P. Infected aortic aneurysms: aggressive presentation,
complicated early outcome, but durable results. J Vasc Surg. 2001;34:900–908.
4. Yu SY, Hsieh HC, Ko PJ, Huang YK, Chu JJ, Lee CH. Surgical outcome for
mycotic aortic and iliac aneurysm. World J Surg. 2011;35:1671–1678.
5. Kyriakides C, Kan Y, Kerle M, Cheshire NJ, Mansﬁeld AO, Wolfe JH. 11-year
experience with anatomical and extra-anatomical repair of mycotic aortic
aneurysms. Eur J Vasc Endovasc Surg. 2004;27:585–589.
6. Touma J, Cochennec F, Parisot J, Fialaire Legendre A, Becquemin JP,
Desgranges P. In situ reconstruction in native and prosthetic aortic infections
using cryopreserved arterial allografts. Eur J Vasc Endovasc Surg.
2014;48:292–299.
7. Jia X, Dong YF, Liu XP, Xiong J, Zhang HP, Guo W. Open and endovascular
repair of primary mycotic aortic aneurysms: a 10-year single-center experi-
ence. J Endovasc Ther. 2013;20:305–310.
8. Brown SL, Busuttil RW, Baker JD, Machleder HI, Moore WS, Barker WF.
Bacteriologic and surgical determinants of survival in patients with mycotic
aneurysms. J Vasc Surg. 1984;1:541–547.
9. Johansen K, Devin J. Mycotic aortic aneurysms. A reappraisal. Arch Surg.
1983;118:583–588.
10. S€orelius K, Mani K, Bj€orck M, Sedivy P, Wahlgren CM, Taylor P, Clough RE,
Lyons O, Thompson M, Brownrigg J, Ivancev K, Davis M, Jenkins MP, Jaffer U,
Bown M, Rancic Z, Mayer D, Brunkwall J, Gawenda M, K€olbel T, Jean-Baptiste E,
Moll F, Berger P, Liapis CD, Moulakakis KG, Langenski€old M, Roos H, Larzon T,
Pirouzram A, Wanhainen A; European MAA collaborators. Endovascular
treatment of mycotic aortic aneurysms: a European multicenter study.
Circulation. 2014;130:2136–2142.
11. S€orelius K, Wanhainen A, Furebring M, Bj€orck M, Gillgren P, Mani K.
Nationwide study of the treatment of mycotic abdominal aortic aneurysms
comparing open and endovascular repair. Circulation. 2016;134:1822–1832.
12. Kan CD, Lee HL, Yang YJ. Outcome after endovascular stent graft treatment for
mycotic aortic aneurysm: a systematic review. J Vasc Surg. 2007;46:906–912.
13. Kan CD, Lee HL, Luo CY, Yang YJ. The efﬁcacy of aortic stent grafts in the
management of mycotic abdominal aortic aneurysm-institute case manage-
ment with systemic literature comparison. Ann Vasc Surg. 2010;24:433–440.
14. Uchida N, Katayama A, Tamura K, Miwa S, Masatsugu K, Sueda T. In situ
replacement for mycotic aneurysms on the thoracic and abdominal aorta using
rifampicin-bonded grafting and omental pedicle grafting. Ann Thorac Surg.
2012;93:438–442.
15. Lin CH, Hsu RB. Primary infected aortic aneurysm: clinical presentation,
pathogen, and outcome. Acta Cardiol Sin. 2014;30:514–521.
16. Berger P, Moll FL. Aortic graft infections: is there still a role for axillobifemoral
reconstruction? Semin Vasc Surg. 2011;24:205–210.
17. Bisdas T, Wilhelmi M, Haverich A, Teebken OE. Cryopreserved arterial
homografts vs silver-coated Dacron grafts for abdominal aortic infections with
intraoperative evidence of microorganisms. J Vasc Surg. 2011;53:1274–1281.
18. Owen K, Wilshaw SP, Homer-Vanniasinkam S, Bojar RA, Berry H, Ingham E.
Assessment of the antimicrobial activity of acellular vascular grafts. Eur J Vasc
Endovasc Surg. 2012;43:573–581.
19. Laine MT, Laukontaus SJ, Sund R, Aho PS, Kantonen I, Alb€ack A, Venermo M. A
population-based study of abdominal aortic aneurysm treatment in Finland
2000 to 2014. Circulation. 2017;136:1726–1734.
20. Daenens K, Fourneau I, Nevelsteen A. Ten-year experience in autogenous
reconstruction with the femoral vein in the treatment of aortofemoral
prosthetic infection. Eur J Vasc Endovasc Surg. 2003;25:240–245.
21. Heinola I, Kantonen I, Jaroma M, Alb€ack A, Vikatmaa P, Aho P, Venermo M.
Editor’s choice—treatment of aortic prosthesis infections by graft removal and
in situ replacement with autologous femoral veins and fascial strengthening.
Eur J Vasc Endovasc Surg. 2016;51:232–239.
22. Bisdas T, Bredt M, Pichlmaier M, Aper T, Wilhelmi M, Bisdas S, Haverich A,
Teebken OE. Eight-year experience with cryopreserved arterial homografts for
the in situ reconstruction of abdominal aortic infections. J Vasc Surg.
2010;52:323–330.
23. Czerny M, von Allmen R, Opfermann P, Sodeck G, Dick F, Stellmes A,
Makaloski V, B€uhlmann R, Derungs U, Widmer MK, Carrel T, Schmidli J. Self-
made pericardial tube graft: a new surgical concept for treatment of graft
infections after thoracic and abdominal aortic procedures. Ann Thorac Surg.
2011;92:1657–1662.
DOI: 10.1161/JAHA.117.008104 Journal of the American Heart Association 8
Biological Repair of Mycotic Aortic Aneurysms Heinola et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 9, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
24. Weiss S, Tobler EL, von Tengg-Kobligk H, Makaloski V, Becker D, Carrel TP,
Schmidli J, Wyss TR. Self made xeno-pericardial aortic tubes to treat
native and aortic graft infections. Eur J Vasc Endovasc Surg. 2017;54:646–
652.
25. Fillmore AJ, Valentine RJ. Surgical mortality in patients with infected aortic
aneurysms. J Am Coll Surg. 2003;196:435–441.
26. Kieffer E, Gomes D, Chiche L, Fleron MH, Koskas F, Bahnini A. Allograft
replacement for infrarenal aortic graft infection: early and late results in 179
patients. J Vasc Surg. 2004;39:1009–1017.
27. Leseche G, Castier Y, Petit MD, Bertrand P, Kitzis M, Mussot S, Besnard M,
Cerceau O. Long-term results of cryopreserved arterial allograft reconstruction
in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta. J
Vasc Surg. 2001;34:616–622.
28. Vogt PR, Brunner-LaRocca HP, Lachat M, Ruef C, Turina MI. Technical details
with the use of cryopreserved arterial allografts for aortic infection: inﬂuence
on early and midterm mortality. J Vasc Surg. 2002;35:80–86.
29. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and
resistance. Clin Microbiol Rev. 1999;12:147–179.
30. Kubota H, Endo H, Noma M, Ishii H, Tsuchiya H, Yoshimoto A, Takahashi Y,
Inaba Y, Nishino Y, Nunokawa M, Hosoi Y, Ikezoe T, Nemoto M, Makino Y,
Nemoto Y, Matsukura M, Sugiyama M, Abe N, Takeuchi H, Nagao G, Kondo E,
Yanagida O, Yoshino H, Sudo K. Xenopericardial roll graft replacement for
infectious pseudoaneurysms and graft infections of the aorta. J Cardiothorac
Surg. 2015;10:133.
31. EVAR trial participants. Endovascular aneurysm repair versus open repair in
patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled
trial. Lancet. 2005;365:2179–2186.
32. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM; EVAR trial investigators.
Endovascular versus open repair of abdominal aortic aneurysm in 15-years’
follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a
randomised controlled trial. Lancet. 2016;388:2366–2374.
33. Dubois M, Daenens K, Houthoofd S, Peetermans WE, Fourneau I. Treatment of
mycotic aneurysms with involvement of the abdominal aorta: single-centre
experience in44consecutivecases.Eur JVascEndovascSurg.2010;40:450–456.
34. M€uller BT, Wegener OR, Grabitz K, Pillny M, Thomas L, Sandmann W. Mycotic
aneurysms of the thoracic and abdominal aorta and iliac arteries: experience
with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg.
2001;33:106–113.
35. Hsu RB, Tsay YG, Wang SS, Chu SH. Surgical treatment for primary infected
aneurysm of the descending thoracic aorta, abdominal aorta, and iliac arteries.
J Vasc Surg. 2002;36:746–750.
36. Sedivy P, Spacek M, El Samman K, Belohlavek O, Mach T, Jindrak V, Rohn V,
Stadler P. Endovascular treatment of infected aortic aneurysms. Eur J Vasc
Endovasc Surg. 2012;44:385–394.
DOI: 10.1161/JAHA.117.008104 Journal of the American Heart Association 9
Biological Repair of Mycotic Aortic Aneurysms Heinola et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 9, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Mani, Ilkka Kantonen and Maarit Venermo
Ivika Heinola, Karl Sörelius, Thomas R. Wyss, Nikolaj Eldrup, Nicla Settembre, Carlo Setacci, Kevin
International Multicenter Study
Open Repair of Mycotic Abdominal Aortic Aneurysms With Biological Grafts: An
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.008104
2018;7:e008104; originally published June 9, 2018;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/7/12/e008104
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on June 9, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
